News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Congressman Donald M. Payne, Jr. Introduces Bipartisan 2016 Colorectal Cancer Detection Act

PDF Legislation aims to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests Berlin (Germany) and Germantown, MD (U.S.A.), September 29, 2016 – Congressman Donald M. Payne, Jr. (D-NJ), today introduced the ”Donald Payne Sr. Colorectal Cancer Detection Act of 2016” at a panel discussion held in Washington D.C. The […]

Read more

Epigenomics AG Announces 2016 Second Quarter and Six Months Financial Results and Reports on Operational Highlights

PDF Revenue increased by 159% in Q2 2016 over same period the prior year Epi proColon® successfully introduced into U.S. market – Leading U.S. laboratory network LabCorp® offers test nationwide Growing momentum in Epi proColon® roll-out as number of ordering U.S. laboratories increases Financial position improved by raising EUR 6.8 million in a private placement […]

Read more

Supervisory Board of Epigenomics AG appoints Gregory Hamilton as Chief Executive Officer (CEO)

PDF Gregory Hamilton has a proven track-record of successfully leading U.S. diagnostics companies Appointment underscores Epigenomics’ ambitions and goals in the U.S. market New CEO to join Epigenomics on July 1, 2016 Berlin (Germany) and Germantown, MD (U.S.A.), June 30, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, […]

Read more

Epigenomics’ Epi proColon® Included in Newly Issued USPSTF Guidelines for Colorectal Cancer Screening

PDF USPSTF recognizes Epi proColon as the only blood-based colorectal cancer screening test Convenient and minimal-invasive blood-based testing contributes to USPSTF´s goal of higher screening participation USPSTF guidelines expected to support adoption of Epi proColon by patients, physicians and insurers Berlin (Germany) and Germantown, MD (U.S.A.), June 16, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, […]

Read more

Epigenomics AG Announces 2016 First Quarter Financial Results and Reports on Operational Highlights

PDF 214 KB 23.05.2016 Berlin (Germany) and Germantown, MD (U.S.A.), May 23, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the first quarter 2016 ending March 31. “During the first quarter 2016, our main efforts were focused on the final steps towards […]

Read more

LabCorp is First U.S. Laboratory Network to Offer Epigenomics’ Epi pro Colon® Colorectal Cancer Screening Test, Nationally Available Immediately

PDF 150 KB 09.05.2016 Berlin (Germany) and Germantown, MD (U.S.A.), May 9, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, announced that Laboratory Corporation of America® Holdings (LabCorp®) is the first laboratory network in the U.S. to offer Epi proColon®, a blood-based test for colorectal cancer screening. Epi […]

Read more
......